PMID- 38125286
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231222
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 14
DP  - 2023
TI  - Group psychedelic therapy: empirical estimates of cost-savings and improved 
      access.
PG  - 1293243
LID - 10.3389/fpsyt.2023.1293243 [doi]
LID - 1293243
AB  - OBJECTIVE: To compare group and individual psychedelic-assisted therapy in terms 
      of clinician time, costs and patient access. METHODS: Using 2023 data from two 
      group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to 
      treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat 
      major depressive disorder (MDD), we compared overall variable costs, clinician 
      costs and clinician time required by therapy protocols utilizing groups versus 
      individual patient therapy. Using published literature, we estimated the 
      prevalence of adults with PTSD and MDD eligible for treatment with psychedelic 
      therapy and projected the savings in time and cost required to treat these 
      prevalent cases. RESULTS: Group therapy saved 50.9% of clinician costs for 
      MDMA-PTSD and 34.7% for psilocybin-MDD, or $3,467 and $981 per patient, 
      respectively. To treat all eligible PTSD and MDD patients in the U.S. in 10 years 
      with group therapy, 6,711 fewer full-time equivalent (FTE) clinicians for 
      MDMA-PTSD and 1,159 fewer for FTE clinicians for psilocybin-MDD would be needed, 
      saving up to $10.3 billion and $2.0 billion respectively, discounted at 3% 
      annually. CONCLUSION: Adopting group therapy protocols where feasible would 
      significantly reduce the cost of psychedelic-assisted therapies. By enhancing the 
      number of patients served per clinician, group therapy could also ameliorate the 
      anticipated shortage of appropriately trained clinicians, thereby accelerating 
      access to these promising new therapies.
CI  - Copyright (c) 2023 Marseille, Stauffer, Agrawal, Thambi, Roddy, Mithoefer, Bertozzi 
      and Kahn.
FAU - Marseille, Elliot
AU  - Marseille E
AD  - School of Public Health, University of California, Berkeley, Berkeley, CA, United 
      States.
FAU - Stauffer, Christopher S
AU  - Stauffer CS
AD  - Department of Psychiatry, Oregon Health and Science University, Portland, OR, 
      United States.
FAU - Agrawal, Manish
AU  - Agrawal M
AD  - Sunstone Therapies, Rockville, MD, United States.
FAU - Thambi, Paul
AU  - Thambi P
AD  - Sunstone Therapies, Rockville, MD, United States.
FAU - Roddy, Kimberly
AU  - Roddy K
AD  - Sunstone Therapies, Rockville, MD, United States.
FAU - Mithoefer, Michael
AU  - Mithoefer M
AD  - College of Medicine, Department of Psychiatry and Behavioral Sciences, Medical 
      University of South Carolina, Charleston, SC, United States.
FAU - Bertozzi, Stefano M
AU  - Bertozzi SM
AD  - School of Public Health, University of California, Berkeley, Berkeley, CA, United 
      States.
FAU - Kahn, James G
AU  - Kahn JG
AD  - Institute for Health Policy Sciences, School of Medicine, University of 
      California, San Francisco, San Francisco, CA, United States.
LA  - eng
PT  - Journal Article
DEP - 20231206
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC10731307
OTO - NOTNLM
OT  - MDMA
OT  - access
OT  - cost
OT  - economics
OT  - psilocybin
OT  - psychedelic-assisted therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/12/21 06:43
MHDA- 2023/12/21 06:44
PMCR- 2023/12/06
CRDT- 2023/12/21 04:10
PHST- 2023/09/12 00:00 [received]
PHST- 2023/11/03 00:00 [accepted]
PHST- 2023/12/21 06:44 [medline]
PHST- 2023/12/21 06:43 [pubmed]
PHST- 2023/12/21 04:10 [entrez]
PHST- 2023/12/06 00:00 [pmc-release]
AID - 10.3389/fpsyt.2023.1293243 [doi]
PST - epublish
SO  - Front Psychiatry. 2023 Dec 6;14:1293243. doi: 10.3389/fpsyt.2023.1293243. 
      eCollection 2023.